Related Experiment Video

Updated: May 27, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Morgane Baron1, Chantal M Boulanger, Bart Staels

  • 1Université Lille Nord de France, Lille, France.

Journal of Cellular and Molecular Medicine
|November 5, 2011
PubMed

Insights

Microparticles (MPs) in blood show altered levels in cardiovascular disease patients, suggesting their potential as biomarkers. Further research is needed to confirm their role in early detection and prognosis.

Area of Science:

  • Biomedical research
  • Cardiovascular science
  • Biomarker discovery

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of death globally.
  • Atherosclerosis, a key contributor to CVDs like heart attack and stroke, develops silently.
  • Circulating biomarkers are crucial for assessing CVD risk and prognosis.

Purpose of the Study:

  • To explore the potential of microparticles (MPs) as biomarkers for cardiovascular diseases.
  • To investigate the role of MPs in the pathophysiology of atherosclerosis.
  • To evaluate the impact of cardiovascular disease treatments on MP levels.

Main Methods:

  • Analysis of microparticle (MP) concentrations in blood samples.
  • Observational studies correlating MP levels with cardiovascular risk factors and events.
  • Investigation of the pathophysiological mechanisms involving MPs in atherosclerosis.
  • Assessment of the effect of pharmacological treatments on plasma MP concentrations.

Main Results:

  • Microparticle (MP) concentrations are modified in patients with cardiovascular risk factors and after cardiovascular events.
  • MPs may play a role in the development of atherosclerosis.
  • Cardiovascular disease medications can decrease plasma MP concentrations.

Conclusions:

  • Microparticles (MPs) show promise as potential biomarkers for cardiovascular diseases.
  • Further prospective studies are essential to validate the predictive value of MPs for early disease detection and progression.
  • Standardization of MP measurement is required for routine clinical application in cardiovascular risk prediction.

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Inflammation01:38

Inflammation

Overview
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...